VectivBio is a clinical-stage biotechnology company.
Vectivbio has raised €303M across 4 funding rounds from 13 investors, most recently a round in Oct 2022. Based in Basel, Switzerland; founded 2019; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-10-20 | Other | €127M | Cowen Healthcare Investments,Driehaus Capital Management,Eventide Asset Management,Forbion's Growth Opportunities Fund,Frazier Life Sciences,Marshall Wace+5 more | View deal → |
| 2022-07-05 | Other | €52M | Forbion Capital Partners,Private investor | View deal → |
| 2020-10-19 | Other | €94M | — | View deal → |
| 2020-09-01 | Series A | €29M | — | View deal → |
